Clinical Scorecard: Impact of Vitamin D3, Omega-3 Fatty Acids, and Physical Activity on Serum Sclerostin Concentrations and Bone Metabolism Indicators

At a Glance

Key Highlights

• SHEP (simple home-based strength exercise program) alone or combined with omega-3s reduced serum sclerostin levels over 3 years.
• Vitamin D3 and omega-3 supplementation alone did not significantly affect serum sclerostin or bone turnover markers (P1NP, β-CTx).
• No significant changes were observed in bone formation (P1NP) or resorption (β-CTx) markers with any intervention or their combinations.

Guideline-Based Recommendations

Diagnosis

• Use serum procollagen type 1 amino-terminal propeptide (P1NP) as a bone formation marker and serum C-terminal telopeptide of type I collagen (β-CTx) as a bone resorption marker.
• Consider serum sclerostin levels as influenced by age, sex, mechanical loading, and metabolic conditions, but interpret with caution due to inconsistent predictive utility.

Management

• Implement simple home-based strength exercise programs (SHEP) to reduce serum sclerostin and potentially enhance bone formation signaling.
• Vitamin D3 supplementation at 2000 IU/day and omega-3 fatty acids at 1 g/day alone are not effective in altering serum sclerostin or bone turnover markers in vitamin D replete older adults.
• Combination of omega-3 supplementation with exercise may have additive effects on lowering sclerostin levels.

Monitoring & Follow-up

• Monitor bone turnover markers (P1NP and β-CTx) to assess bone remodeling activity, especially in response to pharmacological treatments.
• Regularly assess physical activity levels and adherence to exercise programs to optimize bone health outcomes.

Risks

• Romosozumab, a sclerostin antibody, increases bone mineral density but may slightly increase vascular event rates; clinical significance remains unclear.
• Elevated serum sclerostin levels are associated with metabolic disorders and may have complex cardiovascular implications.

Patient & Prescribing Data

Healthy, physically active adults aged 70 years and older, mostly vitamin D replete

SHEP exercise reduces serum sclerostin levels; vitamin D3 and omega-3 supplementation alone do not affect sclerostin or bone turnover markers; combined omega-3 and exercise may enhance sclerostin reduction.

Clinical Best Practices

• Encourage regular simple home-based strength exercises to modulate sclerostin and support bone health in older adults.
• Assess vitamin D status before supplementation; supplementation benefits on bone turnover markers are more evident in deficient individuals.
• Use bone turnover markers P1NP and β-CTx alongside clinical assessment to monitor bone remodeling and fracture risk.
• Interpret serum sclerostin levels cautiously due to variability influenced by multiple factors including age, sex, and comorbidities.

References

• DO-HEALTH Trial ClinicalTrials.gov
• Romosozumab approval and clinical trials